| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 792.56M | 1.06B | 835.61M | 1.09B | 672.65M | 881.14M |
| Gross Profit | 4.76M | 5.95M | 3.01M | 4.70M | -486.00K | -79.57M |
| EBITDA | -13.58M | -18.02M | -18.12M | -15.44M | -19.07M | -95.42M |
| Net Income | -15.89M | -21.00M | -20.84M | -17.46M | -20.50M | -97.63M |
Balance Sheet | ||||||
| Total Assets | 598.59M | 614.60M | 628.86M | 620.41M | 640.56M | 710.60M |
| Cash, Cash Equivalents and Short-Term Investments | 7.83M | 8.20M | 24.35M | 37.58M | 26.65M | 54.37M |
| Total Debt | 24.89M | 30.63M | 34.00M | 9.00M | 15.37M | 21.12M |
| Total Liabilities | 124.69M | 132.28M | 125.61M | 96.32M | 98.91M | 148.38M |
| Stockholders Equity | 473.89M | 482.31M | 503.31M | 524.15M | 541.70M | 562.20M |
Cash Flow | ||||||
| Free Cash Flow | -6.10M | -11.05M | -40.50M | 15.46M | -19.72M | 3.91M |
| Operating Cash Flow | -6.10M | -11.05M | -40.49M | 15.46M | -19.72M | 3.91M |
| Investing Cash Flow | 3.60M | 3.59M | -58.00K | -219.00K | 137.00K | 12.00K |
| Financing Cash Flow | -1.76M | -8.68M | 26.85M | -7.05M | -9.08M | -758.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$299.03M | 9.22 | 4.09% | 7.62% | 6.84% | -0.96% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
54 Neutral | HK$276.80M | -4.96 | -11.41% | 8.70% | -16.95% | -461.16% | |
54 Neutral | HK$2.23B | 62.37 | 15.73% | 0.50% | 11.29% | 40.42% | |
46 Neutral | HK$151.30M | -7.06 | -4.14% | ― | 3.70% | 5.90% | |
46 Neutral | HK$201.50M | -1.39 | -8.93% | ― | -59.19% | -159.11% | |
41 Neutral | HK$375.69M | -1.57 | -13.04% | ― | 8.62% | -24.87% |
Vital Innovations Holdings Limited has announced a change in its company secretary, authorized representative, and process agent roles following the unexpected passing of Mr. Chui Man Lung Everett. Mr. Cheng Chi Chung Kevin has been appointed to these positions, bringing over 14 years of experience in company secretarial services and compliance. This transition is significant for the company’s operations as it ensures continuity in governance and compliance functions, which are crucial for maintaining its standing on the Hong Kong Stock Exchange.
The most recent analyst rating on (HK:6133) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Vital Innovations Holdings Ltd. stock, see the HK:6133 Stock Forecast page.